Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi, miRNA and Epigenetics

Sungwhan An's Biography



Sungwhan An, CEO, Genomictree Inc

Sungwhan An is the founder and Chief Executive Officer of Genomictree, Inc. Molecular diagnostic company based in South Korea since 2000. He also had been worked in Cancer Metastasis Research Center of Yonsei University, College of Medicine, South Korea as an assistant professor from 2003 to 2009. He earned his Ph.D. in the field of molecular virology at the University of Texas at Austin before he went through a postdoctoral training course from 1999 to 2000 at Dr. Harry Greenberg’s lab in the Stanford University School of Medicine where he had been involved in translational research to investigate host cell gene expression profiles when Hepatitis Virus C infected using DNA microarray tool. Current his interest at Genomictree is to discover and develop new DNA methylation biomarkers for the detection of cancers in minimum or non-invasively accessible specimens. In addition, he has established the open platform technique of multiplex assay for the multiple markers and been focusing to extend its utility into the molecular diagnostics for cancer mutations and infectious agents

Sungwhan An Image

Discovery of SDC2 Gene as a Methylation Biomarker and Utility Test in Serum-DNA for the Earlier Detection of Colorectal Cancer

Tuesday, 13 November 2012 at 09:30

Add to Calendar ▼2012-11-13 09:30:002012-11-13 10:30:00Europe/LondonDiscovery of SDC2 Gene as a Methylation Biomarker and Utility Test in Serum-DNA for the Earlier Detection of Colorectal CancerSELECTBIOenquiries@selectbiosciences.com

With an increase in the global incidence of colorectal cancer there is a heightened need for the development of a convenient and high-quality non-invasive screening tests. Widespread use of colonoscopic screening has been limited by cost and low compliance. In the present study the outcome of detecting early stage tumors with SDC2 methylation test in serum DNA is promising enough for this test to be possibly a simple and robust tool to detect more cancers at the stage where treatment outcomes are excellent.


Add to Calendar ▼2012-11-13 00:00:002012-11-14 00:00:00Europe/LondonRNAi, miRNA and EpigeneticsSELECTBIOenquiries@selectbiosciences.com